Direct-acting Antivirals for Patients with Chronic Hepatitis C and Hepatocellular Carcinoma in Taiwan

ConclusionsThe SVR is high within BCLC B HCV-HCC patients by DAAs treatment. The risk of HCC recurrence and progression is not increased by DAAs.
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research